Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Protagenic Therapeutics, Inc.new

Get SEC filing alerts via email and in your feed for Protagenic Therapeutics, Inc.new

PTIX PTIXW

Protagenic Therapeutics, Inc.new

About Protagenic Therapeutics, Inc.new

Protagenic Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing neuropeptide-based therapeutics for stress-related neuropsychiatric and mood disorders. Its lead candidate, PT00114, targets the brain's stress response to treat conditions like depression, anxiety, PTSD, and addiction. The company emphasizes novel mechanisms, proprietary IP, and preclinical efficacy, aiming to advance clinical trials and build a pipeline of differentiated neuropsychiatric treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Protagenic Therapeutics, Inc.new

1
1
Protagenic Therapeutics, Inc.new Protagenic Therapeutics Reports Net Income of $2.2 Million and Significant Asset Growth

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
Protagenic Therapeutics, Inc.new Protagenic Therapeutics Reports Increased Losses and Significant Asset Growth in Latest 10-Q Filing

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Protagenic Therapeutics, Inc.new Protagenic Therapeutics Reports $1.44 Million Net Loss for Fiscal Quarter Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Protagenic Therapeutics, Inc.new Protagenic Therapeutics Reports $5.7 Million Net Loss and Faces Nasdaq Compliance Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Protagenic Therapeutics, Inc.new Protagenic Therapeutics Reports Mixed Financial Results, Operational Challenges, and Strategic Advancements

Via official filing (AI summary) | over 1 year ago | 0 comments